Recursion Pharmaceuticals’ Groundbreaking Cancer Drug Enters Clinical Trials
Company Announcements

Recursion Pharmaceuticals’ Groundbreaking Cancer Drug Enters Clinical Trials

Recursion Pharmaceuticals ( (RXRX) ) just unveiled an announcement.

Recursion Pharmaceuticals, Inc. has announced FDA clearance for the clinical trial of REC-1245, a groundbreaking RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. Leveraging AI and machine learning, Recursion has rapidly transformed REC-1245 from a novel concept to a preclinical drug candidate in less than 18 months, significantly outpacing industry norms. With the potential to serve over 100,000 patients in the US and EU5, REC-1245 is poised to offer new hope for those with limited treatment options, with Phase 1/2 clinical trials set to begin in the fourth quarter of 2024.

Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCathie Wood’s ARK Investment buys 106K shares of Recursion Pharmaceuticals today
TheFlyCathie Wood’s ARK Investment buys 729K shares of Recursion Pharmaceuticals today
TheFlyCathie Wood’s ARK Investment buys 331K shares of Recursion Pharmaceuticals today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App